Features
Integrations
Data Partners
Allocator Intelligence
International
Alternative Channels
Market Intelligence
Investment Firms
Professional Services
Technology
Data sourced from Dakota Private Markets, the private fund performance platform powered by Dakota. Learn More | Request Access
For deal sourcers, staying current on private company activity is critical to spotting active buyers, tracking market trends, and uncovering emerging investment opportunities ahead of competitors.
In October alone, we added more than 2,700+ new private company transactions, bringing the total to over 35,000+ searchable deals across sectors, industries, and transaction types in Dakota Private Markets
Inside Dakota Private Markets, you’ll find the transactions tab that provides structured, filterable data on deal types, values, and dates, while our editorial team curates daily updates through the Dakota transactions newsletter, helping you cut through the noise and focus on what matters most.
To ensure the most comprehensive coverage of private market activity, Dakota’s team monitors over 10,000 websites including company websites, newswires, and numerous third-party news providers to capture and verify transaction data as it happens.
Below are the top 10 health care transactions.
HealthSpan Partners, backed by Bon Secours Mercy Health, agreed to acquire a majority stake in surgical care provider Surgery Partners in a deal valued at roughly USD 6 billion, with closing expected in Q1 2027. Following an unsolicited proposal, the agreement was amended to raise consideration to USD 25.00 per share in cash, plus a 10% annual ticking fee if closing slips past March 1, 2027, for up to USD 26.61 per share and an enterprise value of up to about USD 6.0 billion.
Clayton, Dubilier & Rice (CD&R) agreed on October 6, 2026 to take Option Care Health private in a deal valued at USD 5.8 billion, with McKesson Corporation acquiring a minority stake alongside it. The transaction is supported by USD 3.1 billion of debt financing arranged by Goldman Sachs, Bank of America, and Barclays. Centerview Partners and Kirkland & Ellis advised Option Care Health, and closing is expected in the first half of 2027.
Humana entered a joint venture with BlackRock’s HPS Investment Partners to manage nearly 150 CenterWell Senior Primary Care clinics, replacing the existing CenterWell and WCAS joint ventures. BlackRock will take a majority stake by acquiring WCAS’s equity ownership, valued at approximately USD 2.8 billion, while CenterWell keeps a minority stake and continues to operate the clinics. The deal is expected to close in Q4 2026 and removes the put arrangements that sat as liabilities on Humana’s balance sheet.
STERIS Corporation agreed to acquire a majority stake in Xodus Medical, a Pennsylvania-based maker of surgical safety and patient positioning products, for a purchase price of USD 2.1 billion at closing, plus up to USD 150 million in earnout tied to 2028 performance. Cash tax benefits of about USD 300 million bring the net purchase price to roughly USD 1.8 billion, with financing expected to be primarily debt. The deal expands STERIS’s healthcare consumables and operating room offerings and is expected to close by December 31, 2026.
Shionogi & Co. agreed to acquire IntraBio, an Austin-based biopharmaceutical company focused on rare neurodegenerative diseases, for USD 2.0 billion upfront, making it a wholly owned subsidiary of Shionogi Inc. The deal adds AQNEURSA, which is FDA-approved for Niemann-Pick disease type C and Ataxia-Telangiectasia, and builds on Shionogi’s rare disease push following its RADICAVA acquisition. Closing is planned between November and December 2026, subject to regulatory clearances.
Want to track health care deal activity like this as it happens? Explore the full transactions tab in Dakota Private Markets for real-time, filterable data on every deal in this sector.
Dassault Systèmes completed its acquisition of ArisGlobal from Nordic Capital, which fully exited a partnership dating to 2019, for USD 1.8 billion in cash at closing plus up to USD 200 million tied to AI-related revenue milestones. ArisGlobal’s cloud-native regulatory, safety, and quality platform serves more than 200 life sciences clients and is expected to generate about USD 175 million in 2026 revenue. It will join Dassault’s BIOVIA and MEDIDATA brands in a unified Life Sciences and Healthcare sector led by newly appointed CEO Dr. Ashwini Zenooz.
Viatris agreed to acquire Pacira BioSciences for USD 36.50 per share in cash, an aggregate equity value of USD 1.65 billion, through a tender offer followed by a second-step merger. Pacira brings the non-opioid pain products EXPAREL and ZILRETTA, which generated about USD 746 million in revenue and USD 177 million in adjusted EBITDA over the twelve months ended June 30, 2026. Viatris plans to fund the deal primarily from excess cash, and closing is expected by the end of 2026.
Ferring Pharmaceuticals agreed to acquire a majority stake in Gameto, a biotechnology company using cell engineering to develop women’s reproductive health treatments, in a deal worth up to USD 1.3825 billion subject to development, regulatory, and commercial milestones. Gameto’s selling owners include Overwater Ventures, Insight Partners, RA Capital, and Two Sigma Ventures. The deal remains pending closing, with both companies operating independently until then.
Merck KGaA, Darmstadt, Germany agreed to acquire a majority stake in Silence Therapeutics plc in a strategic acquisition structured as a U.K. scheme of arrangement. The deal was agreed on October 18, 2026 and announced on October 19, 2026, and is valued at USD 1.3 billion with an enterprise value of USD 1.1 billion. Silence Therapeutics shareholders will receive USD 20.00 per ADS, and Morgan Stanley, Centerview Partners, and Cooley LLP were named as advisors. Closing is expected in the first quarter of 2027.
Gilead Sciences agreed to acquire PepStar Therapeutics’ oral IL-23R inhibitor program, including lead asset HCXT-2001, in an asset purchase that gives Gilead worldwide rights to the program. Gilead will pay USD 1.275 billion in upfront cash at closing, which is expected in the fourth quarter of 2026 and is projected to reduce Gilead’s fourth-quarter 2026 GAAP and non-GAAP EPS by approximately USD 0.79 to USD 0.83. The acquisition strengthens Gilead’s inflammation and immunology portfolio, with HCXT-2001 positioned as a potential treatment for immune-mediated inflammatory diseases such as inflammatory bowel disease.
At Dakota, we understand how important it is to stay current on deal activity as it happens. That’s why our editorial team continuously monitors the news for real-time updates on platform investments, add-ons, divestitures, and more to deliver daily highlights straight to your inbox through our transactions newsletter.
Inside Dakota Private Markets, the transactions tab provides structured, filterable data with deal dates, types, sectors, and financials, allowing you to build a customized feed that aligns with your focus areas.
Whether you're evaluating a new investment opportunity or tracking trends within a target sector, Dakota helps you cut through the noise and focus on what matters most.
For more information on these transactions and a deeper dive into their industries and sub-industries, request access to Dakota Private Markets.
Written By: Cate Costin, Marketing Associate
Top 10 Transactions (November 2 - 13)
November 16, 2026
Top 10 Healthcare Transactions: October 2026
November 16, 2026
Top 10 Companies Likely to Transact (November 9 - 13)
November 13, 2026
How to Monitor Private Company Transaction Activity by Sector, Size, and Geography
November 11, 2026
AMD to Acquire Taalas for $2.9 Billion
November 09, 2026
925 West Lancaster Ave
Suite 220
Bryn Mawr, PA 19010
Tel: (610) 642-1481
© Dakota 2026 | Terms of Use | Privacy Policy